Allergic reactions to insulin preparations are not uncommon. Although patients often present with skin symptoms, most articles on insulin allergy are published in endocrinology and allergy journals. The purpose of this report is to describe a case of localized type I allergy to insulin as well as provide a review of the classification of insulin allergy, methods of evaluation, and management options.
Get full access to this article
View all access options for this article.
References
1.
WilliamsJR. A clinical study of the effects of insulin in severe diabetes. J Metab Res, 1922; 2:729-51.
2.
LawrenceRD. Local insulin reactions. Lancet, 1925; 1:1125.
3.
FinebergSE, HuangJ, BrunelleR, et al.Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. Diabetes Care, 2003; 26:89-96.
4.
SchernthanerG. Immunogenicity and allergic potential of animal and human insulins. Diabetes Care, 1993; 16Suppl 3:155-65.
5.
BorcheJE, AndersenKE, Bindslev-JensenC. Cutaneous adverse drug reactions seen at a university hospital department of dermatology. Acta Derm Venereol, 2006; 86:523-7.
HindsKD, KimSW. Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev, 2002; 17;54:505-30.
10.
SchlichtkrullJ, BrangeJ, ChristiansenAH, et al.Clinical aspects of insulin antigenicity. Diabetes, 1972; 21:649-56.
11.
AndersenOO. Insulin antibody formation. II. The influence of species difference and method of administration. Acta Endocrinol, 1973; 72:33-45.
12.
TakumaH, KawagishiT, KyogokuI, et al.A case of primary and generalized allergy to human insulin with no history of any prior insulin exposure. Diabetes Res Clin Pract, 1995; 30:69-73.
13.
GanzMA, UntermanT, RobertsM, et al.Resistance and allergy to recombinant human insulin. J Allergy Clin Immunol, 1990; 86:45-52.
14.
Van HaeftenTW. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care, 1989; 12:641-8.
15.
ReevesWG, BarrD, DouglasCA, et al.Factors governing the human immune response to injected insulin. Diabetologia, 1984; 26:266-71.
16.
SchernthanerG, BorkensteinM, FinkM, et al.Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals. Diabetes Care, 1983; 6Suppl 1:43-8.
17.
McEvoyRC, WittME, Ginsberg-FellnerF, RubinsteinP. Antiinsulin antibodies in children with type I diabetes mellitus. Genetic regulation of production and presence at diagnosis before insulin replacement. Diabetes, 1986; 35:634-41.
18.
SchernthanerG, LudwigH, MayrWR. Immunoglobulin G-insulin antibodies and immune region-associated alloantigens in insulindependent diabetes mellitus. J Clin Endocrinol Metab, 1979; 48:403-7.
19.
CoombsRRA, GellPGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: GellPGH, CoombsRRA, LachmannPJ, editors. Clinical aspects of immunology, 3rd ed. Oxford: Blackwell; 1975. p. 761-81.
20.
DreborgS. Skin tests used in type I allergy testing. Position paper. Allergy, 1989; 44Suppl 10:13-51.
21.
JaegerC, EckhardM, BrendelMD, BretzelRG. Diagnostic algorithm and management of immune-mediated complications associated with subcutaneous insulin therapy. Exp Clin Endocrinol Diabetes, 2004; 112:416-21.
22.
ScheerBG, SitzKV. Suspected insulin anaphylaxis and literature review. J Ark Med Soc, 2001; 97:311-3.
23.
BodtgerU, WittrupM. A rational clinical approach to suspected insulin allergy: status after five years and 22 cases. Diabet Med, 2005; 22:102-6.
24.
GallowayJA, deShazoRD. The clinical use of insulin and the complications of insulin therapy. In: EllenbergM, RifkinH, editors. Diabetes mellitus. Theory and practice, 3rd ed. New Hyde Park: Medical Examination Publishing Co., Inc., New York; 1983. p. 519-38.
25.
YokoyamaH, FukumotoS, KoyamaH, et al.Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering. Diabetes Res Clin Pract, 2003; 61:161-6.
26.
HorrowJC, PharoGH, LevitLS, FreelandC. Neither skin tests nor serum enzyme-linked immunosorbent assay tests provide specificity for protamine allergy. Anesth Analg, 1996; 82:386-9.
27.
ArkinsJA, EngbeingNH, LennonEJ. The incidence of skin reactivity to insulin in diabetic patients. J Allergy, 1962; 33:69-72.
deShazoRD, MatherP, GrantW, et al.Evaluation of patients with local reactions to insulin with skin tests and in vitro techniques. Diabetes Care, 1987; 10:330-6.
30.
TowseA, O'BrienM, TwarogFJ, et al.Local reaction secondary to insulin injection. A potential role for latex antigens in insulin vials and syringes. Diabetes Care, 1995; 18:1195-7.
31.
GrammerLC, ChenPY, PattersonR. Evaluation and management of insulin allergy. J Allergy Clin Immunol, 1983; 71(2):250-4.
FinebergSE, GallowayJA, FinebergNS, et al.Immunogenicity of recombinant human insulin. Diabetologia, 1983; 25:465-9.
34.
FiremanP, FinebergSE, GallowayJA. Development of IgE antibodies to human (recombinant DNA), porcine and bovine insulins in diabetic subjects. Diabetes Care, 1982; 5Suppl 2:119-25.
35.
PattersonR, GrammerLC, ChenPY. Insulin hypersensitivity: pathogenesis, diagnosis and management. In: GuptaS, editor. Immunology of clinical and experimental diabetes. New York: Plenum; 1984. p. 401-14.
36.
DolgerH. The management of insulin allergy and insulin resistance in diabetes mellitus. Med Clin North Am, 1952; 36:783-90.
37.
FrigerioC, AubryM, GomezF, et al.Desensitization-resistant insulin allergy. Allergy, 1997; 52:238-9.
38.
AbrahamMR, Al-SharafiBA, SaavedraGA, KhardoriR. Lispro in the treatment of insulin allergy. Diabetes Care, 1999; 22:1916-7.
39.
PánczélP, HosszúfalusiN, HorváthMM, HorváthA. Advantage of insulin lispro in suspected insulin allergy. Allergy, 2000; 55:418-9.
40.
KaraC, Oguz KutluA, EvliyaogluO, et al.Successful treatment of insulin allergy in a 1-year-old infant with neonatal diabetes by lispro and glargine insulin. Diabetes Care, 2005; 28:983-4.
41.
AiraghiL, LoriniM, TedeschiA. The insulin analog aspart: a safe alternative in insulin allergy. Diabetes Care, 2001; 24:2000.
42.
YasudaH, NagataM, MoriyamaH, et al.Human insulin aspart does not cause insulin allergy. Diabetes Care, 2001; 24:2008-9.
43.
Lluch-BernalM, FernándezM, Herrera-PomboJL, SastreJ. Insulin lispro, an alternative in insulin hypersensitivity. Allergy, 1999; 54:186-7.
44.
BrangeJ, OwensDR, KangS, VolundA. Monomeric insulins and their experimental and clinical implications. Diabetes Care, 1990; 13:923-54.
45.
MoriyamaH, NagataM, FujihiraK, et al.Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes. Diabetes Care, 2001; 24:411-2.
46.
TakataH, KumonY, OsakiF, et al.The human insulin analogue aspart is no the almighty solution for insulin allergy. Diabetes Care, 2003; 26:253-4.
47.
JiXiongX, JianyingL, YulanC, HuixanC. The human insulin analog aspart can induce insulin allergy. Diabetes Care, 2004; 27:2084-5.
48.
Durand-GonzalezKN, GuillausseauN, PecquetC, GaynoJP. Glargine insulin is not an alternative in insulin allergy. Diabetes Care, 2003; 26:2216.
49.
AdachiA, FukunagaA, HorikawaT. A case of human insulin allergy induced by short-acting and intermediate-acting insulin but not by long-acting insulin. Int J Dermatol, 2004; 43:597-9.
50.
ItohM, UchimuraK, MakinoM, et al.Hypersensitivity to regular and intermediate, but not to crystallized insulin as an aggravation factor for underlying bulimia nervosa in a patient with type 1 diabetes. Diabetes Care, 1999; 22:1221-3.
51.
TakatsukiH, IshiiH, YamauchiT, et al.A case of insulin allergy: the crystalline human insulin may mask its antigenicity. Diabetes Res Clin Pract, 1991; 12:137-139.
52.
ValentiniU, CiminoA, RoccaL, et al.CSII in management of insulin allergy. Diabetes Care, 1988; 11:97-8.
Sola-GazagnesA, PecquetC, RadermeckerR, et al.Successful treatment of insulin allergy in a type 1 diabetic patient by means of constant subcutaneous pump infusion of insulin. Diabetes Care, 2003; 56:2961-2.
55.
EapenSS, ConnorEL, GernJE. Insulin desensitization with insulin lispro and an insulin pump in a 5-year old child. Ann Allergy Asthma Immunol, 2000; 85:395-7.
56.
CorcoranAC. Note on rapid desensitization in a case of hypersensitiveness to insulin. Am J Med Sci, 1928; 196:359-61.
57.
WeitzMA. Insulin hypersensitivity with desensitization. J Allergy, 1943; 14:220-6.
58.
MattsonJR, PattersonR, RobertsM. Insulin therapy in patients with systemic insulin allergy. Arch Intern Med, 1975; 135:818-21.
59.
BachmannW, HascheH, MehnertH. Intradermal desensitization with human insulin (recombinant DNA) in a patient with severe allergic skin reaction due to insulin. Diabetes Care, 1982; 5Suppl 2:165-7.
60.
YokayamaH, FukumotoS, KoyamaH, et al.Insulin allergy; desensitization with crystalline zinc-insulin and steroid taper. Diabetes Res Clin Pract, 2003; 61:161-166.
61.
MatheuV, PerezE, HernándezM, et al.Insulin allergy and resistance successfully treated by desensitization with aspart insulin. Clinical Mol Allergy, 2005; 3:16.
62.
BodendorferTW, BrownME, FrankelEH, et al.Desensitization with human (recombinant DNA) insulin. Drug Intell Clin Pharm, 1985; 19:827-9.
63.
LamkinN, LiebermanP, HashimotoK, et al.Allergic reactions to insulin. J Allergy Clin Immunol, 1976; 58:213-23.
64.
BollingerME, HamiltonRG, WoodRA. Protamine allergy as a complication of insulin hypersensitivity: a case report. J Allergy Clin Immunol, 1999; 104:462-5.
ThompsonDM, RoncoJJ. Prolonged desensitization required for treatment of generalized allergy to human insulin. Diabetes Care, 1993; 16:957-8.
67.
ChngHH, LeongKP, LohKC. Primary systemic allergy to human insulin: recurrence of generalized urticaria after successful desensitization. Allergy, 1995; 50(12):984-7.
68.
HoldawayIM, WilsonJD. Cutaneous insulin allergy responsive to oral desensitisation and aspirin. Br Med J, 1984; 289:1565-6.
69.
LoebJA, HeroldKV, BartonKP, et al.Systematic approach to diagnosis and management of biphasic insulin allergy with local anti-inflammatory agents. Diabetes Care, 1989; 12:421-3.
70.
GonzaloMA, ArgilaDDE, GarciaJM, et al.Cutaneous allergy to human (recombinant DNA) insulin. Allergy, 1998; 53:106-7.
71.
SalehiM, D'AlessioDA. New therapies for type 2 diabetes based on glucagon-like peptide 1. Cleve Clin J Med, 2006; 73:382-9.
72.
DeFronzoRA, RatnerRE, HanJ, et al.Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 2005; 28:1092-100.
73.
BuseJB, HenryRR, HanJ, et al.Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 2004; 27:2628-35.
74.
KendallDM, RiddleMC, RosenstockJ, et al.Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 2005; 28:1083-91.
75.
RiddleMC, HenryRR, PoonTH, et al.Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev [Serial online] 2006.
